Table 3

Factors related to lymphoceles in 43 patients among 249 women who underwent surgical treatment for endometrial cancer

VariableN=43χ2 test P valueOR (95% CI)
Age (years) (n (%))
 ≥65 years27 (62.8)0.1401.073 (0.449 to 2.568)
 <65 years16 (37.2)
Body mass index (kg/m2) (n (%))
 ≥3012 (27.9)0.1780.313 (0.123 to 0.794)
 <3031 (72.1)
Comorbidities (n (%))
 Any35 (81.4)0.0924.809 (1.433 to 16.146)
 None8 (18.6)
FIGO stage (n (%))
 ≥II16 (37.2)<0.00115.050 (1.282 to 176.6)
 I27 (62.8)
Tumor grade (n (%))
 G316 (37.2)0.0241.385 (0.469 to 4.093)
 G1–G227 (62.7)
Tumor histology (n (%))
 Adenocarcinoma30 (71.4)0.0301.527 (0.445 to 5.234)
 Not adenocarcinoma12 (28.6)
Myometrial invasion (n (%))
 ≥50%36 (83.7)<0.0012.197 (0.661 to 7.305)
 <50%7 (16.3)
Surgical approach (n (%))
 VLS18 (41.9)0.773–
 LPT25 (58.1)
Harvested pelvic and aortic lymph nodes (n (%))
 ≥1541 (95.4)0.0764.052 (0.935 to 17.564)
 <152 (4.6)
Para-aortic lymphadenectomy (n (%))
 Yes26 (60.5)<0.0015.066 (1.605 to 15.989)
 No17 (39.5)
Positive lymph nodes (n (%))
 Any13 (30.2)<0.0014.069 (0.369 to 44.929)
 None30 (69.8)
Removal of CINDEIN (n (%))
 Any43 (97.7)0.0068.596 (1.144 to 65.591)
 None1 (2.3)
Topical procoagulants (n (%))
 Any31 (72.1)0.0211.758 (0.670 to 4.614)
 No12 (27.9)
Hemovac drainage (n (%))
 Yes43 (100)1.000–
 No0
Adjuvant radiotherapy (n (%))
 Yes33 (76.7)<0.0012.524 (0.875 to 7.285)
 No10 (23.3)
Adjuvant chemotherapy (n (%))
 Yes21 (48.8)<0.0011.056 (0.233 to 4.790)
 No22 (51.2)

  • Multivariated odds ratios (OR) were calculated with their respective 95% confidence intervals (95% CI) through logistic regression analysis.

  • CINDEIN, circumflex iliac nodes distal to the external iliacnodes; FIGO, International Federation of Gynecology and Obstetrics; LPT, laparotomy.